McCullough David 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Jan 5, 2012
Insider Transaction Report
Form 4
Transactions
- Exercise/Conversion
Common Stock
2012-01-03$1.20/sh+60,624$72,749→ 66,624 total - Sale
Common Stock
2012-01-03$2.45/sh−60,624$148,529→ 6,000 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2012-01-03−60,624→ 9,376 totalExercise: $1.20From: 2010-03-02Exp: 2019-03-02→ Common Stock (60,624 underlying)
Footnotes (2)
- [F1]The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.38 to $2.52. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.
- [F2]Transacted under a 10b5-1 plan that was adopted on 12/16/2011.